Amgen Inc. logo

Amgen Inc. (AMGN)

Market Closed
12 Dec, 20:00
BCBA BCBA
AR$
15,980. 00
+120
+0.76%
AR$
152.05B Market Cap
19.61 P/E Ratio
9% Div Yield
1,207 Volume
18.58 Eps
AR$ 15,860
Previous Close
Day Range
15,890 16,030
Year Range
9,750 18,160
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 49 days

Summary

AMGN closed Friday higher at AR$15,980, an increase of 0.76% from Thursday's close, completing a monthly decrease of -7.74% or AR$1,340. Over the past 12 months, AMGN stock gained 52.19%.
AMGN is not paying dividends to its shareholders.
The last earnings report, released on Oct 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 02, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on BCBA (ARS).

AMGN Chart

Similar

MDT
Medtronic Inc.
AR$ 37,580
+0.16%

Amgen Inc. (AMGN) FAQ

What is the stock price today?

The current price is AR$15,980.00.

On which exchange is it traded?

Amgen Inc. is listed on BCBA.

What is its stock symbol?

The ticker symbol is AMGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 9%.

What is its market cap?

As of today, the market cap is 152.05B.

When is the next earnings date?

The next earnings report will release on Feb 02, 2026.

Has Amgen Inc. ever had a stock split?

No, there has never been a stock split.

Amgen Inc. Profile

Biotechnology Industry
Healthcare Sector
Robert A. Bradway CEO
BCBA Exchange
- ISIN
US Country
28,000 Employees
16 May 2025 Last Dividend
- Last Split
17 Jun 1983 IPO Date

Overview

Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.

Products and Services

  • Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
  • Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
  • Prolia - Addresses osteoporosis in postmenopausal women.
  • XGEVA - Prevents skeletal-related events.
  • Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
  • Nplate - Treats immune thrombocytopenia.
  • KYPROLIS - For relapsed or refractory multiple myeloma patients.
  • Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
  • EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
  • Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
  • BLINCYTO - For patients with acute lymphoblastic leukemia.
  • TEPEZZA - Treats thyroid eye disease.
  • KRYSTEXXA - Addresses chronic refractory gout.
  • Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.

Contact Information

Address: One Amgen Center Drive
Phone: 805 447 1000